Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Using a Circulating Tumor Cell Genomic Signature to Predict the Risk of Recurrence in Estrogen Receptor-Positive Breast Cancer

EF 2021-22

Résumé
Breast cancer is one of the leading causes of death in women due to metastasis, (the spreading of cancer from the primary site to other regions). Following surgical removal of the primary tumor, clinicians must decide whether the benefits of additional chemotherapy outweigh its taxing side-effects on the body. When making this decision, they can use a genetic test known as the Oncotype DX which is the gold standard test for predicting the risk of recurrence of certain breast cancers. Recent work in our laboratory has established 2 new characteristics which contribute to metastasis: a unique genetic signature present in cancer cells that circulate in the bloodstream, and the level of genetic diversity between tumor cells from spatially distinct tumor regions. I hypothesize that these characteristics can be used to predict the risk of breast cancer recurrence with similar efficacy as the Oncotype DX can. To test this, I will screen breast tumor samples for our lab’s unique genetic signature and use this data to assign a score of recurrence. The samples I will be assessing have previously been assigned a recurrence score by Oncotype DX which will allow for direct comparison and potential validation of my recurrence test. Next, I will examine cancer genes within cells from different regions of these samples to establish whether the level of spatial genetic diversity in each tumor correlates with the corresponding Oncotype DX score. This work is not only important in validating 2 new metrics for predicting the risk of recurrence in breast cancer, but also for the development of a cheaper, domestic alternative to the Oncotype DX which currently costs our healthcare system $4175 USD per patient and is carried out in the USA.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
480742
Name
Rotbauer Martin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Using a Circulating Tumor Cell Genomic Signature to Predict the Risk of Recurrence in Estrogen Receptor-Positive Breast Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Circulating Tumour Cells; Copy Number Variation; Differential Gene Expression; Intratumour Heterogeneity; Risk Of Recurrence
Abstract
Breast cancer is one of the leading causes of death in women due to metastasis, (the spreading of cancer from the primary site to other regions). Following surgical removal of the primary tumor, clinicians must decide whether the benefits of additional chemotherapy outweigh its taxing side-effects on the body. When making this decision, they can use a genetic test known as the Oncotype DX which is the gold standard test for predicting the risk of recurrence of certain breast cancers. Recent work in our laboratory has established 2 new characteristics which contribute to metastasis: a unique genetic signature present in cancer cells that circulate in the bloodstream, and the level of genetic diversity between tumor cells from spatially distinct tumor regions. I hypothesize that these characteristics can be used to predict the risk of breast cancer recurrence with similar efficacy as the Oncotype DX can. To test this, I will screen breast tumor samples for our lab’s unique genetic signature and use this data to assign a score of recurrence. The samples I will be assessing have previously been assigned a recurrence score by Oncotype DX which will allow for direct comparison and potential validation of my recurrence test. Next, I will examine cancer genes within cells from different regions of these samples to establish whether the level of spatial genetic diversity in each tumor correlates with the corresponding Oncotype DX score. This work is not only important in validating 2 new metrics for predicting the risk of recurrence in breast cancer, but also for the development of a cheaper, domestic alternative to the Oncotype DX which currently costs our healthcare system $4175 USD per patient and is carried out in the USA.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rotbauer, Martin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~